Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,501,091
  • Shares Outstanding, K 1,016,877
  • Annual Sales, $ 18,854 M
  • Annual Income, $ -2,150,000 K
  • 60-Month Beta 1.64
  • Price/Sales 0.44
  • Price/Cash Flow 1.77
  • Price/Book 0.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.55
  • Number of Estimates 8
  • High Estimate 0.57
  • Low Estimate 0.52
  • Prior Year 0.75
  • Growth Rate Est. (year over year) -26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.96 +5.40%
on 06/17/19
12.05 -30.37%
on 05/21/19
-3.24 (-27.86%)
since 05/17/19
3-Month
7.96 +5.40%
on 06/17/19
17.13 -51.02%
on 03/21/19
-8.52 (-50.38%)
since 03/19/19
52-Week
7.96 +5.40%
on 06/17/19
25.96 -67.68%
on 08/21/18
-15.66 (-65.11%)
since 06/19/18

Most Recent Stories

More News
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

AVDL : 2.89 (+5.86%)
JAZZ : 132.16 (+2.39%)
NVS : 90.86 (-0.48%)
TEVA : 8.39 (+0.36%)
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.26 in the latest trading session, marking a -1.59% move from the prior day.

TEVA : 8.39 (+0.36%)
Celgene's Filing for Ozanimod Accepted for Review in US/EU

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

CELG : 97.15 (-0.15%)
NVS : 90.86 (-0.48%)
TEVA : 8.39 (+0.36%)
BIIB : 233.01 (+0.53%)
Biogen Reports Interim Phase III Data on Diroximel Fumarate

Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.

NVS : 90.86 (-0.48%)
TEVA : 8.39 (+0.36%)
ALKS : 22.24 (+0.27%)
BIIB : 233.01 (+0.53%)
Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate

Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.

LLY : 114.65 (+1.10%)
TEVA : 8.39 (+0.36%)
REGN : 306.63 (-1.40%)
PFE : 43.02 (-0.12%)
Teva Settles With Oklahoma, Shares Fall Following Downgrade

Teva (TEVA) plummets after settlement with the state of Oklahoma in a litigation related to its role in opioid epidemic, resulting in a rating downgrade.

MYL : 17.75 (+2.78%)
JNJ : 140.15 (-0.06%)
UBS : 11.79 (+1.03%)
TEVA : 8.39 (+0.36%)
Company News For May 29, 2019

Companies in the news are: UBER, TEVA, AMD and ASGN

ASGN : 57.45 (+2.01%)
AMD : 30.70 (+0.82%)
TEVA : 8.39 (+0.36%)
UBER : 44.20 (+0.78%)
Consumers Around the Country Turn to Over the Counter Drugs for Relief

The lack of accessibility and expensive costs of prescription-based drugs have made it challenging for many consumers to obtain adequate medication. As a result, consumers have begun switching towards...

LLY : 114.65 (+1.10%)
TEVA : 8.39 (+0.36%)
PFE : 43.02 (-0.12%)
CHD : 76.33 (unch)
INNV : 1.4200 (+5.19%)
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL

Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.

ABBV : 78.25 (-0.51%)
TEVA : 8.39 (+0.36%)
RHHBY : 34.8400 (+1.16%)
BMY : 47.72 (-0.15%)
The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

MYL : 17.75 (+2.78%)
NVS : 90.86 (-0.48%)
TEVA : 8.39 (+0.36%)
PFE : 43.02 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade TEVA with:

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

2nd Resistance Point 8.73
1st Resistance Point 8.54
Last Price 8.39
1st Support Level 8.17
2nd Support Level 7.98

See More

52-Week High 25.96
Fibonacci 61.8% 19.08
Fibonacci 50% 16.96
Fibonacci 38.2% 14.84
Last Price 8.39
52-Week Low 7.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar